Dr. Murray Krahn is the Director of THETA (Toronto Health Economics and Technology Assessment Collaborative); F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, University of Toronto; Professor in the Faculties of Medicine and Pharmacy, University of Toronto; Senior Scientist at the Toronto General Hospital Research Institute; and Adjunct Scientist at the Institute for Clinical Evaluative Sciences, Toronto. He is also an attending physician in the division of General Internal Medicine at the University Health Network, Toronto. He completed a Master's Degree in Clinical Epidemiology at McMaster University, and a Clinical Fellowship in Medical Decision Making at the New England Medical Centre in Boston. Dr. Krahn's research program focuses on the use of decision analytic methods to examine health policy and health decision-making. He leads one of the leading technology assessment institutes in the country.
My central area of research interest has been the application of decision analysis and economic evaluation to broad questions of health and clinical policy. This methodologic focus has been expressed in a variety of content areas including prostate cancer and viral hepatitis. More recent interests include evaluating the role of disease specific utility assessment, using administrative data to build longitudinal cost models, and evaluating the role of health technology assessment in pharmaceutical reimbursement decisions.
Value Health Reg Issues. 2019 Aug 27;19:138-144
Health Utility Book (HUB)-Cancer: Protocol for a Systematic Literature Review of Health State Utility Values in Cancer.
MDM Policy Pract. 2019 Jul-Dec;4(2):2381468319852594
Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials.
Syst Rev. 2019 Aug 19;8(1):207
CMAJ. 2019 Jul 02;191(26):E733-E736
Using a Health Economic Framework to Prioritize Quality Indicators: An Example With Smoking Cessation in Chronic Obstructive Pulmonary Disease.
MDM Policy Pract. 2019 Jan-Jun;4(1):2381468319852358
Clinical and Cost-effectiveness of a Comprehensive geriatric assessment and management for Canadian elders with Cancer-the 5C study: a study protocol for a randomised controlled phase III trial.
BMJ Open. 2019 May 10;9(5):e024485
Ann Clin Transl Neurol. 2019 Apr;6(4):642-654
Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB).
Med Decis Making. 2019 Mar 22;:272989X19837969
Chlorhexidine-Related Mortality Rate in Critically Ill Subjects in Intensive Care Units: A Systematic Review and Meta-Analysis.
Respir Care. 2019 Mar;64(3):337-349
The Effect of Cardiac Rehabilitation on Health-Related Quality of Life in Patients With Coronary Artery Disease: A Meta-analysis.
Can J Cardiol. 2019 Mar;35(3):352-364
Senior Scientist, Toronto General Hospital Research Institute (TGHRI)
Director of THETA (Toronto Health Economics and Technology Assessment Collaborative)
F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, University of Toronto
Professor in the Faculties of Medicine and Pharmacy, University of Toronto
Adjunct Scientist at the Institute for Clinical Evaluative Sciences, Toronto.